Yousif Capital Management LLC Sells 7,799 Shares of DexCom, Inc. (NASDAQ:DXCM)

Yousif Capital Management LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 11.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,071 shares of the medical device company’s stock after selling 7,799 shares during the period. Yousif Capital Management LLC’s holdings in DexCom were worth $7,330,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Valley National Advisers Inc. boosted its position in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares during the period. MV Capital Management Inc. raised its stake in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Washington Trust Advisors Inc. raised its stake in shares of DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 193 shares during the last quarter. NBC Securities Inc. bought a new position in shares of DexCom during the third quarter valued at about $47,000. Finally, Thompson Siegel & Walmsley LLC bought a new position in shares of DexCom during the third quarter valued at about $48,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DXCM. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. UBS Group increased their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Raymond James raised their target price on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 23rd. Citigroup raised their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada began coverage on shares of DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $141.40.

Insiders Place Their Bets

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the transaction, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 189,375 shares of company stock worth $25,530,859. Company insiders own 0.41% of the company’s stock.

DexCom Trading Up 0.1 %

Shares of DXCM stock opened at $138.00 on Thursday. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm’s 50 day moving average is $130.58 and its 200 day moving average is $117.88. The stock has a market capitalization of $54.65 billion, a P/E ratio of 105.25, a P/E/G ratio of 2.30 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter last year, the company posted $0.34 earnings per share. The firm’s quarterly revenue was up 26.9% on a year-over-year basis. Research analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.